Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. (Q33403196)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

atypical hemolytic uremic syndrome

12 February 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Moglie Le Quintrec

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

S Krid

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Bertoye

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

V Gueutin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A Lahoche

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

N Heyne

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Ardissino

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

V Chatelet

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

L-H Noël

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Hourmant

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

P Niaudet

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

V Frémeaux-Bacchi

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

E Rondeau

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Legendre

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Loirat

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

French Study Group for Atypical HUS

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

7 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Transplantation

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

3337-3354

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22958221%20AND%20SRC:MED&resulttype=core&format=json

Atypical hemolytic-uremic syndrome

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

New insights into postrenal transplant hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Therapeutic potential of complement modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab and renal transplantation in a patient with CAPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Pathology after eculizumab in dense deposit disease and C3 GN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04252.X